Vanguard Personalized Indexing Management
CRNX

Vanguard Personalized Indexing Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Sell
10,239
-117
-1% -$4.35K ﹤0.01% 1556
2026
Q1 		$376K Buy
10,356
+1,832
+21% +$81.8K ﹤0.01% 1483
2025
Q4 		$397K Buy
8,524
+1,039
+14% +$46.3K ﹤0.01% 1374
2025
Q3 		$312K Buy
+7,485
New +$239K ﹤0.01% 1486

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's CRNX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.1% in Q2 2026, selling an estimated $4.35K and leaving 10,239 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Vanguard Personalized Indexing Management first reported a position in CRNX in Q3 2025 and has held it in 4 quarters since. The position peaked at $397K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 10,239 shares of Crinetics Pharmaceuticals worth $383K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 117 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $4.35K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1556 holding.
  • Vanguard Personalized Indexing Management first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Vanguard Personalized Indexing Management's Crinetics Pharmaceuticals position peaked at $397K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.